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Four new Aib-containing cyclopentapeptides have been synthesized by 
cyclization of the corresponding linear pentapeptides using the DEPC/DIEA method. 
The linear precursors were prepared via the ‘azirine/oxazolone method’, i.e., the Aib 
units were introduced by the reaction of amino acids or peptide acids with a 2,2-
dimethyl-2H-azirin-3-amine, followed by selective hydrolysis of the terminal amide 
function. Most remarkably, cyclo(Aib)5 exists in CDCl3 solution in a symmetrical 
conformation, i.e., no intramolecular H-bonds are detectable. 
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1. Introduction. – Although cyclopeptides have been known for many 
decades, their structures, syntheses and biological activities are of continuing interest 
(see refs. cited in [1]). With regards to their structures, cyclopeptides containing α-
aminoisobutyric acid (Aib) are of special concern because of the conformation 
determining properties of α,α-disubstituted α-amino acids. Besides a few natural 
Aib-containing cyclopeptides [2], several examples have been synthesized, e.g., tetra- 
[3], penta- [4], and hexapeptides [5], as well as examples with larger rings [6]. 
Our studies toward the use of 2,2-disubstituted 2H-azirin-3-amines 1 as 
building blocks in the synthesis of peptides containing α,α-disubstituted glycines [7] 
proved that the ‘azirine/oxazolone method’ constitutes a convenient and efficient 
approach [8]. Based on this method, we have also prepared a series of cyclopeptides 
with Aib or other α,α-disubstituted glycines in their backbone [1][9]. As expected on 
the basis of structural studies of Aib-containing peptides [10], the β-turn motif is also 
a preferred structure of cyclopeptides with α,α-disubstituted glycines in the skeleton 
[1][9][11]. 
In our recent publication [1], we described the cyclization of several 
pentapeptides with 2-methylphenylalanine (Phe(2Me)) and one or two Aib units, e.g. 
2, to give the corresponding cyclopentapeptides, e.g., 3 (Scheme 1). 
 
Scheme 1 
 
In the present study, cyclopentapeptides with three to five Aib units were 
prepared. 
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2. Results and Discussion. – The synthesis of the pentapeptides Z-Gly-Aib-
Acb-Aib-Gly-OMe (4a, Acb = 1-aminocyclobutanecarboxylic acid) and Z-Gly-Aib-
Pro-Aib-Aib-N(Me)Ph (4b) have been described recently [12]. They were 
deprotected in the usual way: saponification of 4a with LiOH.H2O in 
THF/H2O/MeOH gave the peptide acid Z-Gly-Aib-Acb-Aib-Gly-OH (5a, 96%), and 
subsequent hydrogenolysis, either with H2/Pd/C in MeOH or with HCO2NH4/Pd/C in 
MeOH, led to H-Gly-Aib-Acb-Aib-Gly-OH (6a) in quantitative and 95% yield, 
respectively. Selective hydrolysis of 4b with 3N HCl in THF/H2O at room 
temperature yielded Z-Gly-Aib-Pro-Aib-Aib-OH (5b, 70%) [12]. The latter was 
deprotected at the N-terminus to give H-Gly-Aib-Pro-Aib-Aib-OH (6b) 
quantitatively (H2/Pd/C) and in 67% yield (HCO2NH4/Pd/C), respectively.  
The cyclization of the two pentapeptides occurred smoothly by treatment with 
DEPC)/DIEA) 2) in DMF at room temperature to give the cyclopentapeptides 7a and 
7b in 56 and 89% yield, respectively (Fig. 1). The structures were elucidated on the 
basis of the spectroscopic data in comparison with those of the previously reported 
analogues [1]. For example, the dominant peak in the ESI-MS of 7a appeared at m/z 
404 ([M+Na]+) besides the [M+1]+ peak at m/z 382. The 1H-NMR spectrum in CDCl3 
showed four signals for NH groups at 7.21 (s, 2 NH), 7.08 (t-like, 1 NH), 6.57 and 
6.23 ppm (2s, 2 NH) and only two s for the Me groups of two Aib units. In the 13C-
NMR spectrum (CDCl3), five C=O absorptions for lactam groups were present at 
174.9, 174.8, 174.0, 171.8, and 171.4 ppm, and the Me groups of the two Aib units 
appeared at 25.2 and 24.7 ppm. 
 
2)  DEPC = diethyl phosphorocyanidate; DIEA = ethyl(diisopropyl)amine (EtNiPr2, 
Hünig base). 
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Fig. 1. Structures of the cyclopentapeptides 7a and 7b. 
 
For the attempted synthesis of cyclo(Gly-Aib-Aib-Aib-Aib) (7c), two linear 
pentapeptide precursors were prepared according to Schemes 2 and 3. Coupling of Z-
Gly-OH with the known tetrapeptide amide 8 [13] using HBPyU/DIEA 3) gave 4c in 
98% yield (Scheme 2). Deprotection of the latter in the usual way yielded 6c (90%), 
which was cyclized by treatment with DEPC/DIEA at room temperature for 17 h to 
give 7c in 66% yield. 
 
Scheme 2 
 
In the first attempt to prepare the alternative precursor 6d, the dipeptide acid 9 
[13] was coupled with H-Gly-OMe to give, after saponification with LiOH.H2O in 
MeOH, Z-(Aib)2-Gly-OH (10) in 86% yield (Scheme 3). Subsequent coupling of the 
latter with H-(Aib)2-OMe (11a) 4), yielded the protected pentapeptide 4d (74%), 
whose structure was established by X-ray crystallography (Fig. 2). Unexpectedly, all 
attempts to cleave the ester group by treatment with LiOH.H2O to give the 
pentapeptide acid failed. Therefore, the pentapeptide amide 4e was prepared by 
condensation of 10 with H-(Aib)2-N(Me)Ph (11b), which was obtained from Z-
3)  HBPyU = O-(Benzotriazol-1-yl)-N,N,N’,N’-bis(tetramethylen)uronium 
hexafluorophosphate 
4)  Compound 11a was prepared from 9 via esterification with MeOH/BF3.Et2O 
followed by hydrogenolysis with H2/Pd/C at room temperature in 86% yield. The 
product was contaminated with ca. 6% of 3,3,6,6-tetramethylpiperazine-2,5-
dione. 
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(Aib)2-N(Me)Ph [13] by treatment with H2/Pd/C in MeOH. Selective cleavage of the 
terminal amide bond by treatment with 3N HCl in THF/H2O at room temperature and 
subsequent deprotection of the N-terminus via transfer hydrogenolysis led to the 
desired pentapeptide 6d in 95% yield. The cyclization of 6d under the same 
conditions as used in the case of 6c → 7c, but for 63 h, gave the same 
cyclopentapeptide 7c but in the modest yield of 11%. 
 
Scheme 3 
 
In the ESI-MS, characteristic peaks for cyclopentapeptide 7c were the [M+1]+ 
peak at m/z 398 (110%) together with peaks for [M+Na]+ (m/z 420) and [M+K]+ (m/z 
436). The 1H-NMR spectrum in CDCl3 showed a signal for the lactam NH of Gly at 
7.31 ppm (t-like) and four s of Aib-NH at 7.05, 6.65, 6.29 and 6.25 ppm. The lactam 
C=O groups appeared in the 13C-NMR spectrum ast 176.5, 174.7, 174.1, 173.9 and 
172.4 ppm. The eight Me groups of the four Aib units absorbed as four s in the 1H-
NMR spectrum (1.56, 1.55, 1.53, 1.51 ppm) and three signals in the 13C-NMR 
spectrum (25.5, 24.9, 24.8 ppm (ca. 1:2:1)). In addition, four s for C(2) of four Aib 
and a t for CH2 of Gly were detected in the 13C-NMR spectrum. 
 
Fig. 2. ORTEP Plot [14] of the molecular structure of the pentapeptide 4d 
(50% probability ellipsoids, arbitrary numbering of atoms, H-atoms bonded to C-
atoms omitted for clarity) 
 
Suitable crystals of 4d for an X-ray crystal-structure determination were 
obtained from AcOEt/hexane by slow evaporation of the solvent. The molecule 
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adopts an overall helical conformation (Fig. 2). Each NH group of 4d acts as a donor 
for H-bonds (Table 1). Three of them are intramolecular ones, which form a regular 
pattern along the peptide chain: N(1)–H, N(4)–H and N(7)–H interact with the amide 
O-atom that is seven atoms further along the peptide backbone. Each of these 
interactions has a graph set motif [15] of S(10), i.e., three β-turns of type III are 
formed (Table 2) leading to an overall 310-helical conformation of the peptide. The 
remaining N(10)–H and N(13)–H, which are not able to form such intramolecular H-
bonds because of their position in the backbone, form intermolecular H-bonds with 
the ester C=O and amide O-atoms, respectively, at the opposite end of the same 
neighboring molecule. These interactions link the molecules into extended chains 
running parallel to the [10
_
,1] direction; graph sets C(14) for each interaction. 
 
Table 1. Intra- and intermolecular H-bonds of pentapeptide 4d (atom 
numbering refers to Fig. 2) 
 
Table 2. Torsion angles φ, ψ, and ω [°]of the backbone of 4d in the crystal 
 
Finally, the pentapeptide Z-(Aib)5-N(Me)Ph (4f) [13], prepared by repeated 
azirine coupling and selective hydrolysis, was deprotected to give 6f in 94% yield 
(Scheme 4). As 4f was rather insoluble in THF/H2O, the hydrolysis of the terminal 
amide group with 3N HCl had to be performed at 60°. The cyclization of 6f proved to 
be very difficult. Under the usual conditions, with DEPC/DIEA in DMF at room 
temperature as well as at 80°, mixtures of products were obtained, among them 
formylated pentapeptides, H-(Aib)5-OMe, H-(Aib)10-OMe (MS), etc. Also in CH2Cl2 
or in MeCN at reflux, only traces of the desired cyclo[(Aib)5] (7d) could be detected 
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(MS). Finally, after treatment with DEPC/DIEA in DMF at room temperature for 14 
d and repeated chromatographic purification, 7d was obtained in 12% yield. 
 
Scheme 4 
 
The ESI-MS of 7d showed a dominant [M+Na]+ peak (100%) at m/z 448. 
Surprisingly, the 1H-NMR spectrum in CDCl3 showed only two s at 6.63 (NH) and 
1.54 ppm (Me2C) with an intensity ratio of 1:6. Similarly, only three signals appeared 
in the 13C-NMR spectrum (CDCl3): an s at 175.2 (C=O lactam), s at 58.0 (C(2) of 
(Aib)), and q at 25.0 ppm (Me2C of Aib). From these data, we concluded that 
cyclo(Aib)5 (7d) in CDCl3 solution exists in a perfectly symmetrical conformation, 
and no stable intramolecular H-bonds are formed. 
 
3. Conclusions. – Three cyclopentapeptides containing three, four, and five 
Aib-units as well as cyclo(Gly-Aib-Acb-Aib-Gly) were prepared by cyclization of the 
corresponding linear precursors by treatment with DEPC/DIEA in DMF at room 
temperature. The syntheses of the linear pentapeptides were achieved using the 
‘azirine/oxazolone method’ and segment condensation. The results of the cyclization 
reactions show once more (see introduction) that the efficiency of the ring closure 
strongly depends on steric factors, especially at the N-terminal amino acid, i.e., the 
nucleophile in the cyclization. Whereas cyclo[Gly-(Aib)4] was obtained in 66% yield 
from H-Gly-(Aib)4-OH, the yield dropped to 11% in the case of H-(Aib)2-Gly-(Aib)2-
OH. Also, the ring closure of penta-Aib to give cyclo[(Aib)5] occurred only 
sluggishly. 
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Most remarkable are the NMR spectra of cyclo[(Aib)5] as they indicate a 
symmetrical conformation, excluding the presence of stable intramolecular H-bonds. 
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spectra and analyses, and the Stipendienfonds der Basler Chemischen Industrie and 
F. Hoffmann-La Roche AG, Basel, for financial support.  
 
Experimental part 
 
1. Abbreviations. Aib, 2-aminoisobutyric acid (2-methylalanin); DEPC, 
diethyl phosphorocyanidate; DIEA, ethyl(diisopropyl)amine (Hünig base); HBPyU, 
O-(benzotriazol-1-yl)-N,N,N’,N’-bis(tetramethylen)uronium hexafluorophosphate; Z, 
benzyloxycarbonyl. 
2. General. See [1][12]. Solvents were purified by standard procedures. TLC: 
Merck TLC glass plates, silica gel 60 F254. Column chromatography (CC): Uetikon-
Chemie, silica gel C-560 (0.04-0.063 mm) or Merck 60, 0.040–0.063 mm. M.p.: 
Mettler-FP-5 apparatus, uncorrected. [α]D-Values: Perkin-Elmer-241 polarimeter at 
21°. IR Spectra: Perkin-Elmer-781 spectrometer, in KBr. 1H- and 13C-NMR spectra: 
Bruker AC-300, Bruker ARX-300 or Bruker AMX-600 spectrometer at 300 or 600 
(1H) and 75.5 or 150 MHz (13C), respectively, in CDCl3, CD3OD or (D6)DMSO; 
multiplicities of 13C signals determined by the DEPT technique. ESI- and CI-MS: 
Finnigan TSQ-700 and Finnigan SSQ-700 instrument, respectively; m/z (rel. %).  
General Procedure 1 (GP 1; Saponification of Peptide Methylesters). To a 
soln. of a peptide methyl ester (1 mmol) in 10 ml of THF/MeOH/H2O (3:1:1) at 0° 
was added LiOH.H2O (2.5 mmol). The mixture was stirred at 0° for 1 h. Then, it was 
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neutralized by addition of aq. 2N HCl and the org. solvents were evaporated 
(rotavapor). The residue was dissolved in AcOEt und the mixture washed with aq. 
0.5N HCl. The org. phase was dried (Na2SO4) and the solvent evaporated. 
General Procedure 2 (GP 2; Hydrogenolysis). A mixture of Z-protected 
peptide in MeOH and ca. 10% Pd/C (10%) at r.t. was stirred under H2 (balloon) 
overnight. The mixture was filtered through a Celite pad and the solvent of the filtrate 
evaporated to dryness. 
General Procedure 3 (GP 3; Transfer Hydrogenolysis). To a mixture of Z-
protected peptide (1 mmol) and the same amount of Pd/C (10%) in MeOH was added 
CO2NH4 (5 mmol). The mixture was heated at reflux for 10 min, the hot mixture 
filtered through a Celite pad and washed with MeOH. The solvent of the filtrate was 
evaporated to dryness. 
General Procedure 4 (GP 4; Hydrolysis of Peptide Amides). A soln. of Z-
protected peptide amide (1 mmol) in 3N HCl (THF/H2O 1:1) was stirred at r.t. for 1–
4.5 h. Then, 2N HCl was added and the mixture was extracted with Et2O. The org. 
phase was dried (Na2SO4), and the solvent was evaporated. 
General Procedure 5 (GP 5; Cyclization with DEPC). To a ca. 1.5×10–3 M 
soln. of a deprotected pentapeptide (0.1 mmol) in DMF (67 ml) at 0° was added drop-
wise DEPC (0.2–0.4 mmol) and DIEA (1% v/v), and the mixture was stirred 
overnight at r.t. Then, DMF was evaporated and the residue purified 
chromatographically and crystallized. 
General Procedure 6 (GP 6, Segment Condensation). To a mixture of a N-
protected peptide (1 mmol), C-protected amino acid (1.1 mmol), and HBPyU (1 
mmol) in CH2Cl2 (1 ml) at r.t. was added DIEA (2 mmol; 3 mmol in the case of an 
amino acid chloride) and the mixture stirred for 1 h. Then, the solvent was 
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evaporated, the residue was dissolved in AcOEt (20 ml), washed with aq. KHSO4 
(5%, 3×), aq. NaHCO3 (5%, 3×), and aq. NaCl and purified by CC.  
3. Synthesis of cyclo(Gly-Aib-Acb-Aib-Gly) (7a). 3.1. Z-Gly-Aib-Acb-Aib-Gly-
OH (5a). Hydrolysis of Z-Gly-Aib-Acb-Aib-Gly-OMe (4a [12], 215 mg, 0.339 mmol) 
was performed with LiOH.H2O (43 mg, 1.025 mmol) in THF/H2O/MeOH (3:1:1, 4 
ml) according to GP 1: 201 mg (96%) of 5a. Colorless solid. M.p. 89.6–91.4°. IR 
(KBr): 3300s (br), 3060m, 2990m, 2940m, 1755s, 1750s, 1740s, 1730s, 1715s, 1705s, 
1695s, 1670s, 1660s, 1650s, 1645s, 1555s, 1540s, 1535s, 1525s, 1505m, 1470m, 
1465m, 1455m, 1430m, 1415m, 1390m, 1365m, 1340m, 1310m, 1265m, 1240m, 
1185m, 1050m, 1015m, 740m, 695m. 1H-NMR ((D6)DMSO): 8.41, 8.10 (2s, 2 NH); 
7.53 (t-like, NH); 7.3–7.3 (m, 5 arom. H, NH); 7.25 (s, NH); 5.02 (s, PhCH2O); 3.7–
3.6 (m, 2 CH2(Gly)); 2.55–2.4, 2.1–2.0, 1.9–1.75 (3m, 3 CH2(Acb)); 1.36, 1.34 (2s, 2 
Me2C). 13C-NMR ((D6)DMSO): 174.7, 174.5, 172.5, 170.9, 169.8 (5s, 4 CO(amide), 
COOH); 156.7 (s, CO(urethane)); 136.8 (s, 1 arom. C); 128.3, 127.7, 127.5 (3d, 5 
arom. CH); 65.5 (t, PhCH2O); 58.6, 55.9, 55.6 (3s, 2 C(2)(Aib), C(2)(Acb)); 43.7, 
40.8  (2t, 2 CH2(Gly)); 30.4 (t, 2 CH2(Acb)); 25.0, 24.7 (2q, 2 Me2C); 15.0 (t, 
CH2(Acb)). ESI-MS: 556 (100, [M+Na]+), 459 (3, [M–Gly]+), 374 (10, [M–Aib-
Gly]+). 
3.2. H-Gly-Aib-Acb-Aib-Gly-OH (6a). a) Hydrogenolysis of 5a (233 mg, 
0.437 mmol) in MeOH (10 ml) with Pd/C (24 mg) according to GP 2. After addition 
of H2O (10 ml) and filtration through Celite: 177 mg (quant.) of 6a.  
b) Hydrogenolysis of 5a (114 mg, 0.214 mmol) in MeOH according to GP 3 
with Pd/C (114 mg): 81 mg (95%) of 6a. Colorless solid. M.p. 239.2–240.7°. 1H-
NMR (D2O): 3.83, 3.75 (2s, 2 CH2(Gly)); 2.65–2.5, 2.25–2.1, 2.05–1.9 (3m, 3 
CH2(Acb)); 1.52, 1.50 (2s, 2 Me2C). 13C-NMR (D2O): 179.7, 179.0, 177.9, 169.4 (4s, 
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4 CO(amide), COOH); 62.1, 59.5, 59.4 (3s, 2 C(2)(Aib), C(2)(Acb)); 46.3, 43.3  (2t, 
2 CH2(Gly)); 33.3 (t, 2 CH2(Acb)); 27.1, 26.7 (2q, 2 Me2C); 17.7 (t, CH2(Acb)). ESI-
MS: 422 (100, [M+Na]+). 
3.3. Cyclo(Gly-Aib-Acb-Aib-Gly) (7a). The cyclization of 6a (27.3 mg, 0.068 
mmol) in DMF (45 ml) was carried out with DEPC (125.5 mg, 0.77 mmol) and DIEA 
(0.45 ml) according to GP 5. After CC (CH2Cl2/MeOH/NH3 10:1:0.1) and 
crystallization from CHCl3/hexane, 14.5 mg (56%) of 7a were obtained. Colorless 
solid. M.p. 135.3–136.4°. 1H-NMR (CDCl3): 7.21 (s, 2 NH); 7.08 (t-like, NH); 6.57, 
6.23 (2s, 2 NH); 3.99 (d, J = 6.3, CH2(Gly)); 3.85 (d, J = 6.4, CH2(Gly)); 2.6–2.45,  
2.4–2.3, 2.15–2.0, 2.0–1.8 (4m, 2:2:1:1, 3 CH2(Acb)); 1.58, 1.55 (2s, 2 Me2C). 13C-
NMR (CDCl3): 174.9, 174.8, 174.0, 171.8, 171.4 (5s, 5 CO(amide)); 60.1, 57.7, 57.4 
(3s, 2 C(2)(Aib), C(2)(Acb)); 44.7, 44.0  (2t, 2 CH2(Gly)); 31.1 (t, 2 CH2(Acb)); 25.2, 
24.7 (2q, 2 Me2C); 15.7 (t, CH2(Acb)). ESI-MS: 404 (100, [M+Na]+), 382 (7, 
[M+1]+). 
4. Synthesis of cyclo(Gly-Aib-Pro-Aib-Aib) (7b). 4.1. H-Gly-Aib-Pro-Aib-Aib-
OH (6b). a) Hydrogenolysis of 5b [12] (86 mg, 0.153 mmol) in MeOH (3 ml) with 
Pd/C (8.7 mg) according to GP 2. After 10 min, the reaction was complete (TLC) and 
a precipitate formed, which dissolved again during stirring overnight: 66 mg (quant.) 
of 6b.  
b) Hydrogenolysis of 5b (330 mg, 0.588 mmol) in MeOH  (3 ml) according to 
GP 3 with HCO2NH4 (183 mg, 2.902 mmol) and Pd/C (331 mg): 81 mg (95%) of 6b. 
Colorless solid. M.p. 173.6–175.3°. IR (KBr): 3320m, 3050m, 2980m, 2930m, 
2870m, 1670s, 1620s, 1550s, 1470m, 1450m, 1415m, 1390m, 1360m, 1280m, 1210m, 
1190m, 1170m. 1H-NMR (D2O): 4.33 (t-like, CH(2)(Pro)); 3.89 (s, CH2(Gly)); 3.8–
3.65, 3.6–3.5 (2m, CH2(5)(Pro)); 2.3–2.15, 2.1–1.8 (2m, 1:3, CH2(3), CH2(4)(Pro)); 
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1.51, 1.48, 1.43, 1.42 (4s, 1:3:1:1, 3 Me2C). 13C-NMR (D2O): 184.5, 178.2, 176.7, 
176.4, 168.5 (5s, 4 CO(amide), COOH); 65.7 (d, CH(2)(Pro)); 60.5, 59.6 (2s, 1:2, 3 
C(2)(Aib)); 51.7 (t, CH2(5)(Pro)); 42.8 (t, CH2(Gly)); 31.0, 28.3 (2t, CH2(3), 
CH2(4)(Pro)); 27.2, 27.04, 26.97, 26.4 (4q, 3 Me2C). ESI-MS: 466 (23, [M+K]+, 450 
(100, [M+Na]+), 428 (52, [M+1]+), 325 (16, [M–Aib]+), 286 (20, [Pro-Aib-Aib]+). 
4.2. Cyclo(Gly-Aib-Pro-Aib-Aib) (7b). The cyclization of 6b (48.2 mg, 0.113 
mmol) in DMF (75 ml) was carried out with DEPC (67.0 mg, 0.411 mmol) and DIEA 
(0.75 ml) according to GP 5. After CC (CH2Cl2/MeOH 10:1) and crystallization from 
AcOEt/hexane, 41.2 mg (89%) of 7b were obtained. Colorless solid. M.p. 139.1–
140.5°. [α]D20 = –35.6 (c = 0.95, EtOH). IR (KBr): 3300s, 3040m, 2980m, 2940m, 
1695s, 1680s, 1670s, 1660s, 1650s, 1645s, 1635s, 1565m, 1555s, 1550s, 1540s, 
1520s, 1505s, 1480m, 1470m, 1460m, 1455m, 1445m, 1390s, 1365s, 1270m, 1245m, 
1215m, 1195m, 1175m, 1075m, 1050m, 1030m.  1H-NMR ((D6)DMSO): 8.7 (very br. 
s, NH); 7.83 (br. s, NH); 7.30 (br. s, NH); 6.8 (very br. s, NH); 4.5–4.35 (m, 
CH(2)(Pro)); 4.15–3.8 (m, 1 H of CH2(Gly)); 3.55–3.3 (m, CH2(5)(Pro), 1 H of 
CH2(Gly)); 2.0–1.75 (m, CH2(3), CH2(4)(Pro)); 1.49, 1.44, 1.40, 1.31 (4s, 1:2:2:1, 3 
Me2C). ESI-MS: 432 (100, [M+Na]+), 410 (20, [M+1]+). 
5. Synthesis of cyclo(Gly-Aib-Aib-Aib-Aib) (7c). 5.1. Via Cyclization of H-
Gly-Aib-Aib-Aib-Aib-OH (6c). 5.1.1. Z-Gly-Aib-Aib-Aib-Aib-N(Me)Ph (4c). 
According to GP 6, to a mixture of H-Aib-Aib-Aib-Aib-N(Me)Ph (8 [13], 202.6 mg, 
0.453 mmol), Z-Gly-OH (98.2 mg, 0.469 mmol), and HBPyU (202.7 mg, 0.470 
mmol) in CH2Cl2 (4 ml) at r.t. was added DIEA (119.7 mg, 0.926 mmol). After 
stirring for 21 h, the precipitate was filtered and washed with a little CH2Cl2 to give 
4c (243.7 mg) as a white powder. The filtrate was evaporated, and CC 
(CH2Cl2/MeOH) gave additional 40.7 mg of 4c. Total yield: 284.4 mg (98%). 
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Colorless powder. M.p. 222.3–224.4°. IR (KBr): 3310m, 3280m, 2980m, 2940m, 
1700m, 1680s, 1670s, 1660s, 1645s, 1635s, 1590m, 1530s, 1495m, 1465m, 1450m, 
1395m, 1380m, 1360m, 1270m, 1230m, 1170m, 1090m, 710m. 1H-NMR (CD3OD): 
7.4–7.2 (m, 10 arom. H); 5.10 (s, PhCH2O); 3.71 (s, CH2(Gly)); 3.38 (s, MeN); 1.55, 
1.48, 1.41, 1.38 (4s, 4 Me2C). 13C-NMR (CD3OD): 177.1, 176.7, 176.4, 175.9, 172.1 
(5s, 5 CO(amide)); 159.4 (s, CO(urethane)); 147.2, 138.2 (2s, 2 arom. C); 130.3, 
129.6, 129.1, 128.8, 128.2, 128.1 (6d, 10 arom. CH); 67.8 (t, PhCH2O); 58.4, 58.2, 
57.9, 57.6 (4s, 4 C(2)(Aib)); 45.2 (t, CH2(Gly)); 41.1 (q, MeN); 26.3, 26.0, 25.34, 
25.27 (4q, 4 Me2C). ESI-MS: 661 (16, [M+Na]+), 532 (100, [M–N(Me)Ph]+), 447 
(49, [M–Aib-N(Me)Ph]+), 362 (18, [M–Aib-Aib-N(Me)Ph]+). 
5.1.2. Z-Gly-Aib-Aib-Aib-Aib-OH (5c). According to GP 4, 4c (255.8 mg, 
0.400 mmol) was hydrolyzed in 3N HCl (THF/H2O 1:1, 10 ml, 1 h). Extraction with 
AcOEt gave 213.4 mg (97%) of 5c. A sample was recrystallized from boiling AcOEt. 
Colorless needles. M.p. 201.8–203.0°. IR (KBr): 3340s, 3310s, 3300s, 3080m, 
3070m, 3060m, 3040m, 2980m, 2940m, 2930m, 1730s, 1715s, 1710s, 1695s, 1680s, 
1670s, 1660s, 1650s, 1645s, 1550s, 1540s, 1520s, 1510s, 1470m, 1455s, 1385s, 
1365m, 1280s, 1240s, 1230s, 1170s, 1160s, 1155s, 1050m, 735m, 700m. 1H-NMR 
(CD3OD): 7.7–7.6 (m, 2 arom. H); 7.4–7.3 (m, 3 arom. H); 5.10 (s, PhCH2O); 3.72 (s, 
CH2(Gly)); 1.49, 1.42, 1.41, 1.39 (4s, 4 Me2C). 13C-NMR (CD3OD): 178.3, 176.9, 
176.6, 172.1 (4s, 4 CO(amide), COOH); 159.8 (s, CO(urethane)); 138.2 (s, arom. C); 
129.6, 129.1, 128.8 (3d, 5 arom. CH); 67.9 (t, PhCH2O); 57.9, 57.7, 57.1 (3s, 4 
C(2)(Aib)); 45.3 (t, CH2(Gly)); 25.7, 25.41, 25.36, 25.3 (4q, 4 Me2C). CI-MS: 551 
(23), 550 (79, [M+1]+), 533 (26), 532 (93, [M–OH]+), 448 (24), 447 (100, [M–Aib-
OH]+), 442 (32), 424 (10), 416 (18, [M–BnCO2]+), 398 (12), 362 (32, [M–Aib-Aib-
 15 
OH]+), 104 (73, [H-Aib-OH+1]+). Anal. calc. for C24H36N4O7 . 0.5 H2O (558.63): C 
55.90, H 7.22, N 12.54; found: C 55.80, H 7.14, N 12.44. 
5.1.3. H-Gly-Aib-Aib-Aib-Aib-OH (6c). According to GP 3, 5c (187.7 mg, 
0.342 mmol) was deprotected by treatment with HCO2NH4 (109.8 mg, 1.741 mmol) 
and Pd/C (188.0 mg) in MeOH (7 ml): 132.3 mg (93%) of 6c. Colorless solid. 1H-
NMR (D2O): 3.84 (s, CH2(Gly)); 1.48, 1.47, 1.43, 1.42 (4s, 4 Me2C). 13C-NMR 
(D2O): 179.0, 178.8, 178.5, 169.3 (4s, 4 CO(amide), COOH); 60.6, 59.7 (2s, 4 
C(2)(Aib)); 43.3 (t, CH2(Gly)); 27.2, 27.1, 26.9, 26.8 (4q, 4 Me2C). CI-MS: 417 (29), 
416 (100, [M+1]+), 398 (14, [M–OH]+).  
5.1.4. Cyclo(Gly-Aib-Aib-Aib-Aib) (7c). According to GP 5, to a soln. of 6c 
(38.6 mg, 0.093 mmol) in DMF (63 ml) were added DEPC (46.6 mg, 0.286 mmol) 
and DIEA (0.6 ml) at r.t. After stirring for 17 h, DMF was evaporated and the residue 
purified by CC (CH2Cl2/MeOH 10:1): 24.5 mg (66%) of 7c. Colorless solid. M.p. 
126.3–127.7°. IR (KBr): 3330m, 2980w, 2940w, 1690s, 1680s, 1670s, 1660s, 1650s, 
1645s, 1635s, 1550s, 1540s, 1530s, 1515s, 1505s, 1470m, 1460m, 1390m, 1375m, 
1225m.  1H-NMR (CDCl3): 7.31 (t-like, NH); 7.05, 6.65, 6.29, 6.25 (4s, 4 NH); 3.39 
(d, J = 6.1, CH2(Gly)); 1.56, 1.55, 1.53, 1.51 (4s, 4 Me2C). 13C-NMR (CDCl3): 176.5, 
174.7, 174.1, 173.9, 172.4 (5s, 5 CO(amide)); 59.1, 57.6, 57.4, 56.9 (4s, 4 
C(2)(Aib)); 45.1 (t, CH2(Gly)); 25.5, 24.9, 24.8 (3q, 4 Me2C). ESI-MS: 436 (12, 
[M+K]+), 420 (19, [M+Na]+), 398 (100, [M+1]+).  
5.2. Via Cyclization of H-Aib-Aib-Gly-Aib-Aib-OH (6d). 5.2.1. Z-Aib-Aib-
Gly-OMe. According to GP 6, with Z-Aib-Aib-OH (9 [13], 797.1 mg, 2.473 mmol), 
H-Gly-OMe.HCl (343.1 mg, 2.733 mmol), HBPyU (1.070 g, 2.480 mmol) and DIEA 
(1.3 ml, 7.594 mmol) in CH2Cl2 (7 ml); reaction time 2.5 h. The precipitate was 
filtered to give 550.3 mg tripeptide; the filtrate was evaporated, and CC (AcOEt) 
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gave an additional portion of tripeptide. Total yield: 906.8 mg (93%). Colorless solid. 
M.p. 151.5–152.2°. IR (KBr): 3350s, 3280s, 3040m, 2980m, 2950m, 1755m, 1700s, 
1670s, 1660s, 1535s, 1520s, 1455m, 1435m, 1410m, 1385m, 1370m, 1265m, 1215s, 
1210s, 1195s, 1175s, 1090m, 1080s, 985m, 965m, 755m, 700m. 1H-NMR (CDCl3): 
7.42 (br. s, NH); 7.4–7.3 (m, 5 arom. H); 6.46, 5.32 (2s, 2 NH); 5.10 (s, PhCH2O); 
3.99 (d, J = 5.6, CH2(Gly)); 3.72 (s, MeO); 1.48 (s, 2 Me2C). 13C-NMR (CDCl3): 
174.6, 173.1, 170.5 (3s, 2 CO(amide), COOMe); 155.7 (s, CO(urethane)); 136.0 (s, 
arom. C); 128.7, 128.5, 128.4 (3d, 5 arom. CH); 67.1 (t, PhCH2O); 57.3, 57.1 (2s, 2 
C(2)(Aib)); 51.9 (q, MeO); 41.4 (t, CH2(Gly)); 25.43, 25.38 (2q, 2 Me2C). CI-MS: 
412 (6), 411 (30, [M+NH4]+), 395 (21), 394 (100, [M+1]+), 331 (14), 306 (22), 305 
(8). Anal. calc. for C19H27N3O6 (393.44): C 58.00, H 6.92, N 10.68; found: C 57.88, 
H 7.04, N 10.62. 
5.2.2. Z-Aib-Aib-Gly-OH (10). According to GP 1, Z-Aib-Aib-Gly-OMe 
(906.8 mg, 2.305 mmol) was saponified with LiOH.H2O (243.0 mg, 5.791 mmol) in 
THF/MeOH/H2O (3:1:1, 7 ml): 809 mg (93%). Colorless solid. IR (KBr): 3320s, 
3300s, 3085m, 3030m, 3000m, 2940m, 2910m, 2900m, 1765m, 1750m, 1702s, 1665s, 
1620s, 1615s, 1565s, 1515s, 1470m, 1450m, 1410m, 1385m, 1370m, 1335m, 1265s, 
1220m, 1175s, 1085s, 900m, 740m, 695m. 1H-NMR (CD3OD): 7.90 (br. s, NH); 7.74 
(s, NH); 7.4–7.25 (m, 5 arom. H); 5.09 (s, PhCH2O); 3.89–3.87 (m, CH2(Gly)); 1.42, 
1.39 (2s, 2 Me2C). 13C-NMR (CD3OD): 177.6, 176.7, 173.0 (3s, 2 CO(amide), 
COOH); 158.1 (s, CO(urethane)); 138.2 (s, arom. C); 129.6, 129.24, 129.18 (3d, 5 
arom. CH); 67.8 (t, PhCH2O); 58.0, 57.8 (2s, 2 C(2)(Aib)); 42.0 (t, CH2(Gly)); 25.4 
(q, 2 Me2C). CI-MS: 398 (6), 397 (36, [M+NH4]+), 381 (19), 380 (100, [M+1]+), 305 
(15, [M–Gly]+), 289 (17), 272 (16), 246 (30, [M–BnOCO]+.  
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5.2.3. Z-Aib-Aib-OMe [16]. To a soln. of Z-Aib-Aib-OH [13] (1.070 g, 3.317 
mmol) in MeOH (30 ml) was added BF3.Et2O (0.42 ml) and the mixture stirred for 18 
h. The solvent was evaporated, the residue dissolved in CH2Cl2 (150 ml), and the 
mixture extracted with aq. 2N HCl (2×), aq. 1N NaOH (2×) and brine, dried (MgSO4), 
and the solvent evaporated. Crystallization from AcOEt/hexane yielded Z-Aib-Aib-
OMe (1.075 g, 97%). Colorless solid. M.p. 107.4–108.6°. IR (KBr): 3380m, 3360m, 
3320s, 3280s, 3030m, 2980m, 2950m, 1730s, 1715s, 1660s, 1545m, 1535s, 1520s, 
1470m, 1465m, 1450m, 1435m, 1385m, 1360m, 1300m, 1255s, 1225m, 1215m, 
1190m, 1170m, 1155m, 1085m, 1070s, 960m, 745m, 695m. 1H-NMR (CDCl3): 7.4–
7.3 (m, 5 arom. H); 6.90 (br. s, 1 NH); 5.31 (br. s, 1 NH); 5.09 (s, PhCH2O); 3.72 (s, 
MeO); 1.51, 1.50 (2s, 2 Me2C). 13C-NMR (CDCl3): 175.0, 173.5 (2s, CO(amide), 
COOMe); 155.1 (s, CO(urethane)); 136.3 (s, arom. C); 128.5, 128.2, 128.1 (3d, 5 
arom. CH); 66.7 (t, PhCH2O); 57.0, 56.5 (2s, 2 C(2)(Aib)); 52.2 (q, MeO); 25.4, 24.5 
(2q, 2 Me2C). CI-MS: 338 (17), 337 (100, [M+1]+), 230 (5), 229 (59). Anal. calc. for 
C17H24N2O5 (336.39): C 60.70, H 7.19, N 8.33; found: C 60.92, H 7.38, N 8.36. 
5.2.4. H-Aib-Aib-OMe [16] (11a). According to GP2, Z-Aib-Aib-OMe (204.8 
mg, 0.609 mmol) im MeOH (3 ml) was deprotected (19.6 mg Pd/C, 30 min): 109.5 
mg (89%) of 11a (contaminated with ca. 6% of 3,3,6,6-tetramethylpiperazine-2,5-
dione [17]). 1H-NMR ((D6)DMSO): 8.03 (s, NH); 3.57 (s, MeO); 2.45–1.7 (br. 
signal, NH2); 1.38, 1.15 (2s, 2 Me2C). 13C-NMR ((D6)DMSO): 177.0, 174.4 (2s, 
CO(amide), COOMe); 54.7, 54.0 (2s, 2 C(2)(Aib)); 51.7 (q, MeO); 28.3, 24.6 (2q, 2 
Me2C). CI-MS: 405 (23, [2M+1]+), 204 (9), 203 (100, [M+1]+).  
5.2.5. H-Aib-Aib-N(Me)Ph (11b). According to GP2, Z-Aib-Aib-N(Me)Ph 
[13] (613 mg, 1.490 mmol) im MeOH (2 ml) was deprotected (10 mg Pd/C, 30 min): 
413 mg (quant.) of 11b. Colorless oil. 1H-NMR (CDCl3): 7.68 (br. s, NH); 7.45–7.25 
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(m, 5 arom. H); 3.27 (s, MeN); 1.48 (br. s, NH2); 1.49, 1.25 (2s, 2 Me2C). 13C-NMR 
(CDCl3): 175.9, 173.4 (2s, 2 CO(amide)); 145.2 (s, arom. C); 129.3, 128.0, 127.6 (3d, 
5 arom. CH); 57.4, 54.9 (2s, 2 C(2)(Aib)); 41.4 (q, MeN); 28.8, 26.6 (2q, 2 Me2C).  
5.2.6. Z-Aib-Aib-Gly-Aib-Aib-OMe (4d). According to GP 6, with 10 (138.8 
mg, 0.366 mmol), freshly prepared 11a (82.3 mg, 0.407 mmol), HBPyU (158.2 mg, 
0.367 mmol), and DIEA (131 mg, 1.014 mmol) in CH2Cl2 (3 ml); reaction time 2 h. 
The precipitate formed during evaporation was filtered to give 103.2 mg 4d; the 
filtrate was evaporated, and CC (AcOEt) gave an additional portion of 4d. Total 
yield: 151.9 mg (74%). Colorless solid. M.p. 175.3–176.1°. IR (KBr): 3350s, 3320s, 
3300s, 3260s, 3040m, 2980m, 2940m, 1760s, 1700s, 1680s, 1665s, 1660s, 1650s, 
1540s, 1515s, 1470m, 1465m, 1455m, 1410m, 1385m, 1360m, 1305m, 1265s, 1230m, 
1215m, 1195m, 1160m, 1080s, 700m. 1H-NMR (CDCl3): 7.74 (t-like, NH); 7.33 (br. 
s, 5 arom. H, NH); 7.08, 6.55, 6.05 (3s, 3 NH); 5.09 (s, PhCH2O); 3.70 (d, J = 5.8, 
CH2(Gly)); 3.66 (s, MeO); 1.53, 1.51, 1.48, 1.39 (4s, 4 Me2C). 13C-NMR (CDCl3): 
175.5, 175.3, 174.5, 174.3, 169.0 (5s, 4 CO(amide), COOMe); 156.5 (s, 
CO(urethane)); 136.0 (s, arom. C); 128.7, 128.6, 128.1 (3d, 5 arom. CH); 67.5 (t, 
PhCH2O); 57.1, 56.7, 55.8 (3s, 4 C(2)(Aib)); 52.1 (q, MeO); 44.7 (t, CH2(Gly)); 25.4, 
25.13, 25.08, 25.0 (4q, 4 Me2C). ESI-MS: 586 (100, [M+Na]+). Anal. calc. for 
C27H41N5O8 (563.65): C 57.54, H 7.43, N 12.42; found: C 57.54, H 7.20, N 12.21. 
Crystals suitable for an X-ray crystal-structure determination were grown 
from AcOEt/hexane by slow evaporation of the solvent. 
5.2.7. Z-Aib-Aib-Gly-Aib-Aib-N(Me)Ph (4e). According to GP 6, with 10 
(386.5 mg, 1.019 mmol), 11b (338.2 mg, 1.219 mmol), HBPyU (442 mg, 1.025 
mmol), and DIEA (309 mg, 2.391 mmol) in CH2Cl2 (5 ml); reaction time 16 h. 
Purification by CC (CH2Cl2/MeOH 20:1) gave 529.8 mg (81%) of 4e. A sample was 
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recrystallized from CH2Cl2/hexane. Colorless crystals. M.p. 199.7–201.4°. IR (KBr): 
3310s, 3250m, 2980m, 1690s, 1680s, 1660s, 1645s, 1595m, 1495m, 1470m, 1455m, 
1435m, 1395m, 1385m, 1360m, 1270s, 1215m, 1195m, 1175m, 1090m, 1070m, 700m. 
1H-NMR (CD3OD): 7.45–7.25 (m, 10 arom. H); 5.11 (s, PhCH2O); 3.62 (s, 
CH2(Gly)); 3.36 (s, MeN); 1.53, 1.51, 1.41, 1.35 (4s, 4 Me2C). 13C-NMR (CD3OD): 
178.5, 177.4, 176.5, 175.6, 171.8 (5s, 5 CO(amide)); 158.5 (s, CO(urethane)); 147.0, 
138.5 (2s, 2 arom. C); 130.3, 129.6, 129.2, 128.9, 128.4 (5d, 10 arom. CH); 68.0 (t, 
PhCH2O); 58.5, 57.2 (2s, 4 C(2)(Aib)); 45.3 (t, CH2(Gly)); 41.1 (q, MeN); 26.4, 26.0, 
25.4, 25.3 (4q, 4 Me2C). ESI-MS: 661 (100, [M+Na]+), 532 (6, [M–N(Me)Ph]+).  
5.2.8. Z-Aib-Aib-Gly-Aib-Aib-OH. According to GP 4, 4e (448.5 mg, 0.702 
mmol) was hydrolyzed in 3N HCl (THF/H2O 1:1; 7 ml): 370.2 mg (96%) of Z-Aib-
Aib-Gly-Aib-Aib-OH. Colorless solid. M.p. 215.4–216.8°. IR (KBr): 3300s, 3060m, 
3040m, 2990m, 2940m, 1720s, 1695s, 1670s, 1660s, 1550m, 1540s, 1530s, 1525s, 
1470m, 1460m, 1455m, 1385m, 1365m, 1270s, 1220m, 1170m, 1090m, 1080m, 700m. 
1H-NMR (CD3OD): 7.45–7.3 (m, 5 arom. H); 5.11 (s, PhCH2O); 3.64 (s, CH2(Gly)); 
1.49, 1.48, 1.41, 1.36 (4s, 4 Me2C). 13C-NMR (CD3OD): 178.3, 178.0, 177.4, 176.2, 
171.8 (5s, 4 CO(amide), COOH); 158.5 (s, CO(urethane)); 138.5 (s, arom. C); 129.6, 
129.2, 128.9 (3d, 5 arom. CH); 68.0 (t, PhCH2O); 58.2, 57.8, 57.7, 57.1 (4s, 4 
C(2)(Aib)); 45.0 (t, CH2(Gly)); 25.7, 25.4, 25.30, 25.27 (4q, 4 Me2C). ESI-MS: 572 
(100, [M+Na]+). 
5.2.9. H-Aib-Aib-Gly-Aib-Aib-OH (6d). According to GP 3, Z-Aib-Aib-Gly-
Aib-Aib-OH (281.5 mg, 0.513 mmol) was deprotected in MeOH (9 ml) by treatment 
with HCO2NH4 (163 mg, 2.585 mmol) and Pd/C (280.3 mg): 214.0 mg (quant.) of 
6d. Colorless solid. 1H-NMR (D2O): 3.85 (s, CH2(Gly)); 1.64, 1.51, 1.49, 1.43 (4s, 4 
Me2C). 13C-NMR (CD3OD): 184.7, 179.9, 177.8, 175.2, 173.2 (5s, 4 CO(amide), 
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COOH); 60.8, 60.0, 59.3 (3s, 4 C(2)(Aib)); 46.0 (t, CH2(Gly)); 27.1, 26.9, 26.7, 25.9 
(4q, 4 Me2C). ESI-MS: 416 (100, [M+1]+). 
5.2.10. Cyclo(Gly-Aib-Aib-Aib-Aib) (7c). According to GP 5, to a soln. of 6d 
(27.2 mg, 0.066 mmol) in DMF (45 ml) were added DEPC (34.0 mg, 0.21 mmol) and 
DIEA (0.4 ml) at r.t. After stirring for 63 h, DMF was evaporated and the residue 
purified by CC (CH2Cl2/MeOH 20:1→10:1): 2.8 mg (11%) of 7c.  
6. Synthesis of cyclo(Aib-Aib-Aib-Aib-Aib) (7d). 6.1. Z-Aib-Aib-Aib-Aib-Aib-
OH. According to GP 4, Z-Aib-Aib-Aib-Aib-Aib-N(Me)Ph (4f [13], 881.1 mg, 1.321 
mmol) was hydrolyzed at 60° for 1 h. The precipitate was filtered and washed with 
Et2O to give 726.8 mg of Z-Aib-Aib-Aib-Aib-Aib-OH. Extraction of the aq. phase 
with Et2O (4×) gave additional 34.0 mg of the product. Total yield: 760.8 mg 
(quant.). Colorless solid. M.p. 226.2–227.3°. IR (KBr): 3410s, 3320s, 3290s, 3250s, 
3040s, 2980s, 2940s, 2920m, 2900m, 1745s, 1730s, 1710s, 1705s, 1695s, 1680s, 
1675s, 1665s, 1645s, 1635s, 1580m, 1565m, 1550s, 1530s, 1515s, 1465s, 1455s, 
1445s, 1385s, 1365s, 1320s, 1315s, 1280s, 1270s, 1265s, 1225s, 1210s, 1185s, 
1180s, 1170s, 1165s, 1090s, 1080s, 955m, 945m, 750m, 700m. 1H-NMR 
((D6)DMSO): 11.83 (br. s, COOH); 8.23, 7.85, 7.46 (3s, 3 NH);  7.4–7.3 (m, 5 arom. 
H, 1 NH); 7.28 (s, NH); 5.09 (s, PhCH2O); 1.33, 1.32, 1.21 (3s, 3:1:1, 5 Me2C). 13C-
NMR ((D6)DMSO): 175.5, 174.9, 174.7, 173.42, 173.38 (5s, 4 CO(amide), COOH); 
155.7 (s, CO(urethane)); 137.1 (s, arom. C); 128.3, 127.6, 127.1 (3d, 5 arom. CH); 
65.4 (t, PhCH2O); 55.9, 55.81, 55.76, 55.6, 54.5 (5s, 5 C(2)(Aib)); 25.0, 24.6, 24.5, 
24.3 (4q, 5 Me2C). ESI-MS: 660 (100, [M+Na]+), 578 (80, [M+1]+), 560 (8, [M–
OH]+), 475 (19, [M–Aib-OH]+). Anal. calc. for C28H43N5O8 (577.68): C 58.22, H 
7.50, N 12.12; found: C 58.36, H 7.30, N 11.93. 
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6.2. H-Aib-Aib-Aib-Aib-Aib-OH (6f). According to GP 3, Z-Aib-Aib-Aib-
Aib-Aib-OH (233.2 mg, 0.404 mmol) in MeOH (7 ml) was deprotected by treatment 
with HCO2NH4 (129.5 mg, 2.054 mmol) and Pd/C (240 mg). The crude material was 
dissolved in MeOH and precipitated with Et2O to give 169.8 mg (95%) of 6f. 
Colorless powder. 1H-NMR (D2O): 7.54, 7.52 (2s, 2 NH); 1.65, 1.48, 1.43, 1.42 (4s, 
1:2:1:1, 5 Me2C). 13C-NMR (D2O): 178.9, 178.6, 178.4, 175.3 (4s, 4 CO(amide), 
COOH); 60.1, 59.9, 59.7, 59.6 (4s, 5 C(2)(Aib)); 27.2, 27.1, 26.9, 26.5, 25.9 (5q, 5 
Me2C). ESI-MS: 466 (7, [M+Na]+), 444 (100, [M+1]+).  
6.3. Cyclo(Aib-Aib-Aib-Aib-Aib) (7d). To a soln. of 6f (171.3 mg, 0.386 
mmol) in DMF (260 ml) were added DEPC (294.8 mg, 1.807 mmol) and DIEA (2.6 
ml) at r.t. After stirring at r.t. for 2 weeks, DMF was removed in HV and subsequent 
CC (CH2Cl2/MeOH 15:1, 3×) yielded 30.7 mg of a mixture of 7d and an unknown 
compound. Additional CC (AcOEt/MeOH 20:1, 2×) gave 19.7 mg (12%) 7d. 
Colorless powder. M.p. > 260°. IR (KBr): 3420m, 3320s, 3120m, 2990m, 2980m, 
2940m, 1690s, 1670s, 1650s, 1570s, 1520s, 1480m, 1450m, 1385s, 1360s, 1310m, 
1280s, 1220s, 1210s, 1185m, 1170m. 1H-NMR (CDCl3): 6.63 (s, 5 NH); 1.54 (s, 5 
Me2C). 13C-NMR (CDCl3): 175.2 (s, 5 CO(lactam)); 58.0 (s, 5 C(2)(Aib)); 25.0 (q, 5 
Me2C). ESI-MS: 448 (100, [M+Na]+).  
7. X-Ray Crystal-Structure Determination of 4d (see Table 3 and Fig. 2)5). 
The measurements were made on a Rigaku AFC5R diffractometer using graphite-
monochromated MoKα radiation (λ  0.71073 Å) and a 12 kW rotating anode 
5)  CCDC-1034190 contains the supplementary crystallographic data for this 
paper. These data can be obtained free of charge from The Cambridge 
Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. 
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generator. The intensities were corrected for Lorentz and polarization effects. 
Azimuthal scans of several reflections indicated no need for an absorption correction. 
Equivalent reflections were merged. The data collection and refinement parameters 
are given in Table 3, and a view of the molecule is shown in Fig. 2. The structure was 
solved by direct methods using SHELXS86 [18], which revealed the positions of all 
non-H-atoms. The non-H-atoms were refined anisotropically. The amide H-atoms 
were placed in the positions indicated by a difference electron density map and their 
positions were allowed to refine together with individual isotropic displacement 
parameters. All remaining H-atoms were placed in geometrically calculated positions 
and refined by using a riding model where each H-atom was assigned a fixed 
isotropic displacement parameter with a value equal to 1.2Ueq of its parent C-atom 
(1.5Ueq for the Me groups). The refinement of the structure was carried out on F2 by 
using full-matrix least-squares procedures, which minimized the function Σw(Fo2 – 
Fc2)2. A correction for secondary extinction was applied. Neutral atom scattering 
factors for non-H-atoms were taken from [19], and the scattering factors for H-atoms 
were taken from [20].  Anomalous dispersion effects were included in Fc [21]; the 
values for ƒ’ and ƒ” were those of [22]. The values of the mass attenuation 
coefficients are those of [23]. The SHELXL-2014 program [24] was used for all 
calculations. 
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Legends 
 
 
Fig. 1. Structures of the cyclopentapeptides 7a and 7b. 
 
Fig. 2. ORTEP Plot [14] of the molecular structure of the pentapeptide 4d (50% 
probability ellipsoids, arbitrary numbering of atoms, H-atoms bonded to C-atoms 
omitted for clarity) 
 
 
Table 1. Intra- and intermolecular H-bonds of pentapeptide 4d (atom numbering 
refers to Fig. 2) 
 
Table  2. Torsion angles φ, ψ, and ω [°] of the backbone of 4d in the crystal 
 
Table 3.  Crystallographic Data for Compound 4d  
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Table 1. Intra- and intermolecular H-bonds of pentapeptide 4d (atom numbering 
refers to Fig. 2) 
 
 
Donor…Acceptor           N…O [Å]             H…O [Å]              N–H…O [°] 
 
 
N(1)–H…O(8)                2.952(3)               2.10(3)                 167(2) 
N(4)–H…O(11)              3.053(3)               2.21(3)                 169(2) 
N(7)–H…O(14)              2.879(3)               2.05(3)                 158(2) 
N(10)–H…O(24’)           3.053(3)               2.21(3)                 164(2) 
N(13)–H…O(2’)             2.860(3)               2.03(3)                 168(2) 
 
 
 
Table  2. Torsion angles φ, ψ, and ω [°] of the backbone of 4d in the crystal 
 
 
φ(i) ψ(i)                    ω(i)                     φ(i+1)                 ψ(i+1)                ω(i+1) 
 
 
–54.1(3)      –42.1(3)     –177.3(2)   –55.2(3)      –27.5(3)     –179.3(2) 
 
 
φ(i+2) ψ(i+2)                ω(i+2)                φ(i+3)                 ψ(i+3)                ω(i+3)           φ(i+4) ψ(i+4) 
 
 
–58.4(3)      –23.7(3)     174.9(2)     –60.4(3)      –20.2(3)     –176.9(2)   55.1(3)       44.5(3)  
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Table 3.  Crystallographic Data for Compound 4d  
______________________________________________________________________________________________ 
 
Crystallized from AcOEt/hexane 
Empirical formula C27H41N5O8 
Formula weight 563.65 
Crystal color, habit colorless, needle 
Crystal dimensions [mm] 0.20 × 0.25 × 0.45 
Temperature [K] 173(1) 
Crystal system monoclinic 
Space group P21/n 
Z 4  
Reflections for cell determination 25 
2θ range for cell determination [°] 20–37 
Unit cell parameters a [Å] 11.674(2) 
 b [Å] 16.174(2) 
 c [Å] 16.774(2) 
 β [°] 103.29(1) 
 V [Å3] 3082.1(8) 
Dx [g cm-3] 1.215 
µ(MoKα) [mm-1] 0.090  
Scan type ω/2θ 
2θ(max) [°] 55 
Total reflections measured 7404 
Symmetry independent reflections 7068 
Reflections with I > 2σ(I) 3881 
Reflections used in refinement  7068 
Parameters refined 391 
Final R(F)  [I > 2σ (I) reflections] 0.0530 
 wR(F2) (all data) 0.1412 
Weighting parameter (a)a) 0.0513 
Goodness of fit 1.003 
Secondary extinction coefficient 0.0018(5)   
Final ∆max/σ 0.000 
∆ρ (max; min) [e Å–3] 0.25; –0.23 
_________________________________________________________________________________ 
a) w–1 = σ2 (Fo2) + (aP)2, where P = (Fo2 + 2Fc2)/3
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Scheme 3 
 
 
 
Scheme 4 
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Figure 1 
 
 
 
 Figure 2  
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